Latest & greatest articles for albuterol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on albuterol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on albuterol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for albuterol

21. Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Full Text available with Trip Pro

Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Article Text Therapeutics Levalbuterol reduced admissions more than racemic albuterol in children with acute asthma Free Thomas

2005 Evidence-Based Medicine

22. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED

Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED Schreck D M, Babin S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of racemic albuterol 2.5 mg or levalbuterol 1.25 mg delivered via a nebuliser, in the emergency department (ED), in addition to other standard treatments such as corticosteroids and oxygen. Treatment choice was determined by the attending physician. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

2005 NHS Economic Evaluation Database.

23. Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain

Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

24. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.

Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

25. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. (Abstract)

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. The issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2 (...) -adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial.Patients with mild asthma, not using a controller medication, were enrolled in pairs matched for forced expiratory volume in 1 s (FEV1) according to whether they had the Arg/Arg (n=37; four of 41 matches withdrew before randomisation) or Gly/Gly (n=41) genotype. Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over design, for 16-week

2004 Lancet Controlled trial quality: predicted high

26. Albuterol Sulfate HFA Inhalation Aerosol

Albuterol Sulfate HFA Inhalation Aerosol Drug Approval Package: Albuterol Sulfate HFA Inhalation Aerosol NDA #021457 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Albuterol Sulfate HFA Inhalation Aerosol Company: IVAX Research, Inc. Application No.: 021457 Approval Date: 10/29/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: April 30, 2007 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help

2004 FDA - Drug Approval Package

27. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. (Abstract)

Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Intravenous magnesium can cause bronchodilation in treatment of severe asthma, however its effect by the nebulised route is uncertain. We aimed to assess the effectiveness of isotonic magnesium sulphate as an adjuvant to nebulised salbutamol in severe attacks of asthma.We enrolled 52 patients with severe exacerbations of asthma presenting (...) to the emergency departments at two hospitals in New Zealand. A severe exacerbation was defined as a forced expiratory volume at 1 s (FEV(1)) of less than 50% predicted 30 min after initial administration of 2.5 mg salbutamol via nebulisation. In this randomised double-blind placebo-controlled trial patients received 2.5 mg nebulised salbutamol mixed with either 2.5 mL isotonic magnesium sulphate or isotonic saline on three occasions at 30 min intervals. The primary outcome measure was FEV(1) at 90 min

2003 Lancet Controlled trial quality: predicted high

28. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma

Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma Truitt T, Witko J, Halpern M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of racemic albuterol (RA) versus levalbuterol (LEV) for the inpatient treatment of patients with chronic obstructive pulmonary disease (COPD) or asthma. The patients in the RA group were treated with a target care path of 2.5 mg every 4 hours and as medically necessary. The patients in the LEV group were

2003 NHS Economic Evaluation Database.

29. A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis

A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club

30. Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol

Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol Drug Approval Package: Ventolin-HFA (Albuterol Sulfate) NDA #20-983 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Ventolin-HFA (Albuterol Sulfate) Inhalation Aerosol Company: GlaxoSmithKline Application No.: 20-983 Approval Date: 4/19/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: November 20, 2001 Note: Documents in PDF format

2001 FDA - Drug Approval Package

31. AccuNeb (Albuterol Sulfate) Inhalation

AccuNeb (Albuterol Sulfate) Inhalation Drug Approval Package: AccuNeb (Albuterol Sulfate) NDA #020949 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - AccuNeb (Albuterol Sulfate) Inhalation Company: Dey Laboratories Application No.: 020949 Approval Date: 4/30/2001 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: January 28, 2005 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2001 FDA - Drug Approval Package

32. A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates

A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2001 NHS Economic Evaluation Database.

33. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. (Abstract)

Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Previous work has suggested that the long-term regular use of inhaled beta2-agonist bronchodilators might lead to a deterioration in asthma control. The aim of TRUST (The Regular Use of Salbutamol Trial) was to study the effects of regular use of inhaled salbutamol, the most widely prescribed bronchodilator in the UK (...) . Patients were randomised to receive 400 microg salbutamol or matched placebo via a Diskhaler four times per day for 12 months. The primary outcome measure was rate of exacerbations of asthma, with criteria based on data from diary cards completed daily by each patient, treatment with additional corticosteroids, or both.There were no differences in the annual rate, timing, or duration of exacerbations between the two groups. The mean morning peak expiratory flow was similar for the two groups. The mean

2000 Lancet Controlled trial quality: predicted high

34. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical technology: ipratropium combined with albuterol in a single inhalational canister (Combivent; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). Type of intervention Treatment. Economic

1999 NHS Economic Evaluation Database.

35. The Use of Albuterol in Hospitalized Infants With Bronchiolitis

The Use of Albuterol in Hospitalized Infants With Bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1998 PedsCCM Evidence-Based Journal Club

36. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. (Abstract)

Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. The mainstay of treatment for acute asthma in children is nebulised beta 2-adrenergic agents such as salbutamol, given with corticosteroids. However, penetration of the drug to the small airways is impeded by obstruction so intravenous salbutamol may be more effective. We assessed the use of intravenous salbutamol in the management of children with acute severe asthma in a double-blind randomised (...) study.Children who presented to the Emergency Department of Westmead Hospital, Sydney, Australia with asthma were assessed with a clinical assessment scale, and those with severe acute asthma were given nebulised salbutamol at a dose of 2.5 mg (age < or = 2 years) or 5.0 mg (age > 2 years), made up to 4 mL with saline. Children who did not improve were eligible to enter phase one of the study. In this phase (0 h-2 h) treatment was by a standard protocol: nebulised salbutamol at the above dose: 4 L/min or 6 L

1997 Lancet Controlled trial quality: predicted high

37. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: A randomized, controlled trial

Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: A randomized, controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1997 PedsCCM Evidence-Based Journal Club

38. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. (Abstract)

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.In a multicenter, double-blind (...) study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both

1996 NEJM Controlled trial quality: uncertain

39. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. (Abstract)

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. In view of current concerns about use of regular beta-2 agonists, and the place of the newer long-acting drugs, we decided to evaluate whether continuous exposure to twice daily salmeterol results in a blunting of the acute bronchodilator response to repeated doses of salbutamol, as might be administered in the management of an acute asthma attack. After a 2 week run-in without beta-2 agonists, 17 (...) asthmatic patients (mean [SE] age 34 [3] years, mean forced expiratory volume in 1 s [FEV1] 64 [2.7]% of predicted) were randomised to receive salmeterol 50 micrograms twice daily or placebo for 4 weeks in a double-blind cross-over fashion. A histamine challenge test was done 12 h after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 micrograms) were constructed 36 h after the last dose. Patients treated with salmeterol had reduced bronchodilator

1995 Lancet Controlled trial quality: uncertain

40. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. (Abstract)

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma.Randomized, double-blind, placebo-controlled, parallel-group study.Eleven outpatient clinical centers.A total of 322 male and female patients at least 12 years of age with chronic symptomatic asthma (...) requiring daily therapy.Patients were treated with salmeterol xinafoate (42 micrograms inhaled twice daily), albuterol (180 micrograms inhaled four times daily), or placebo (four times a day) for 12 weeks; patients in all three groups could use inhaled albuterol as backup medication for breakthrough symptoms.Serial 12-hour forced expiratory flow in 1 second (FEV1), peak expiratory flow (PEF), asthma symptoms, nocturnal awakenings due to asthma, episodes of asthma exacerbations

1994 JAMA Controlled trial quality: predicted high